Listing 1 - 2 of 2 |
Sort by
|
Choose an application
The idea of combining drugs and diagnostics in oncology is not new. When the selective estrogen receptor modulator tamoxifen was developed in the 1970’s for the treatment of breast cancer a positive correlation between receptor status and treatment outcome was found. As a result of this research, it was suggested to use the estrogen-receptor assay as a diagnostic test for selection of patients for tamoxifen treatment. Despite this suggestion was put forward nearly 40 years ago the adaptation of the drug-diagnostic co-development model has been relatively slow and it is only within the last decade that it has gained more widespread acceptance. The parallel development of the monoclonal antibody trastuzumab (Herceptin®, Roche/Genentech) and the immunohistochemistry assay for HER2 protein overexpression (HercepTest™, Dako) seems to have served as an inspiration to a number of stakeholders such as pharma and diagnostic companies, regulatory agencies, and academia. In recent years we have seen an increasing number of oncology drug development projects that have taken advantage of the drug-diagnostic co-development model, as outline below. Most of the new targeted anti-cancer drugs that have been introduced in recent years, such as BRAF-, ALK-, EGFR- and HER2-inhibitors, are more or less all a product of the drugdiagnostic co-development model. These drugs have shown remarkable high response rates in selected groups of patients within cancer diseases with great unmet medical needs.
Oncology. --- Tumors --- IHC --- fish --- precision medicine --- NGS --- Drug-diagnostic co-development --- companion diagnostics --- oncology --- personalized medicine
Choose an application
This reprint is related to the latest research in the field of thyroid surgery, including molecular and imaging diagnosis, surgical treatment, and the treatment of recurrent disease and advanced thyroid carcinoma.
Medicine --- Oncology --- thyroid carcinoma --- prophylactic central lymph node dissection --- lymph node metastases --- RET --- medullary thyroid carcinoma --- clinical management --- variants of uncertain significance --- differentiated thyroid cancer --- papillary thyroid cancer --- minimal extrathyroidal extension --- radioactive iodine therapy --- prognosis --- TNM --- histology --- multifocality --- lymph node metastasis --- vascular invasion --- autoimmune thyroid diseases --- radioiodine refractory --- Lenvatinib --- 18F-FDG-PET/CT --- cost-benefit analysis --- economics --- medical --- thyroid neoplasms --- radiomics --- ultrasound --- magnetic resonance imaging --- computer tomography --- prediction --- classification --- angiogenic microenvironment --- prognostic factors --- antiangiogenic therapy --- therapeutic target --- tumor microenvironment --- tumor behavior --- proliferation pathways --- cell cycle control pathways --- angiogenesis process --- thyroid cancer --- Gal-3 expression --- NIFTP --- EFVPTC --- lymphocytic thyroiditis (LT) --- immunohistochemical (IHC) analysis --- molecular imaging --- theranostics --- companion diagnostics --- immunoPET --- anaplastic thyroid cancer --- poorly thyroid cancer --- genetic landscape --- genetically guided therapy --- fluorodeoxyglucose F18 (18F-FDG) --- positron emission tomography (PET) --- magnetic resonance imaging (MRI) --- recurrence --- neoplasm metastasis --- thyroid surgery --- hypoparathyroidism --- fluorescence-guided surgery --- near-infrared autofluorescence --- PRKAR1A --- PKA --- Carney complex --- cAMP --- bone metastasis --- metastasectomy --- stereotactic radiosurgery --- ultrasound imaging --- thyroid nodule --- fine-needle aspiration --- papillary thyroid carcinoma --- lobectomy --- operative extent --- CONUT score --- tyrosine kinase inhibitors
Listing 1 - 2 of 2 |
Sort by
|